One Shot to Silence a Disease: Intellia's CRISPR Bet Just Paid Off

Lonvo-z's pitch is fundamentally different: get one infusion, and you may be done. That's a seismic shift in how we think about treating genetic diseases. Not managing them; correcting them.

Clean Safety, No Red Flags

Gene editing inside a living human body sounds like it should come with a long list of scary side effects. But through the data cutoff, the safety profile was remarkably clean. The most common side effects were the kind you'd expect from any IV infusion: infusion-related reactions, headache, fatigue, back pain, and upper respiratory infections.

The critical detail: no serious adverse events were reported in the lonvo-z arm. All treatment-related side effects were mild or moderate. For a therapy that literally edits your DNA in vivo (inside your body, not in a lab), that's a reassuring signal. It won't eliminate long-term safety questions entirely, but it gives regulators a lot less to worry about.

The FDA Is Already Moving Fast

Intellia didn't waste time after the data readout. The company initiated a rolling BLA submission (essentially filing its FDA application in chunks as sections were ready) back in April 2026, thanks to its Regenerative Medicine Advanced Therapy designation. The FDA accepted the application in September 2026 and granted Priority Review, which means the agency considers this a potential significant improvement over existing treatments.

The PDUFA date, the FDA's deadline to make an approval decision, is set for March 10, 2027. If everything goes smoothly, Intellia expects a U.S. commercial launch in the first half of 2027.

The CRISPR Race Has a Clear Frontrunner

Intellia isn't the only company betting on in vivo gene editing, but it's the one furthest down the track. CRISPR Therapeutics has its own liver-directed programs (CTX310, CTX340, CTX321), with CTX310 showing early promise as a single-dose cholesterol-lowering treatment. Verve Therapeutics is pursuing a similar "one and done" concept for cardiovascular disease, though it uses base editing rather than traditional CRISPR-Cas9. Editas Medicine is even earlier, targeting first human dosing for its EDIT-401 program in 2026.

But none of them have what Intellia now holds: phase 3 data proving a single in vivo CRISPR infusion can durably control a disease. That's a first. And in biotech, firsts matter enormously, both for regulatory precedent and for investor confidence.

Wall Street's Reaction: Cautiously Optimistic

You might expect a stock to skyrocket after data like this. The reality has been more measured. Intellia's shares popped about 8% on the Priority Review news.

So why the gap between the science and the stock? A few reasons. Intellia is a clinical-stage biotech, which means it's still burning cash without product revenue. The broader biotech market has been unkind to small-cap names. And investors are weighing the rest of Intellia's pipeline, not just HAE. The HAELO data de-risked this one program significantly, but the company's overall story is still being written.

The Bigger Picture

Zoom out for a second. Five years ago, the idea of editing genes inside a living person to treat disease felt like science fiction. Vertex and CRISPR Therapeutics broke ground with Casgevy, the first approved CRISPR therapy, but that involved editing cells outside the body and transplanting them back in.

What Intellia is doing is different. Lonvo-z goes straight into the bloodstream, finds the liver, and edits genes right where they sit. If this gets approved, it won't just be a win for HAE patients. It'll be proof of concept that in vivo CRISPR editing works as a therapeutic platform, opening the door for dozens of other genetic diseases.

One infusion. 87% fewer attacks. 62% of patients completely attack-free. No serious side effects. A March 2027 FDA decision date.

For a field that's been long on promise and short on proof, this is the kind of moment that changes the conversation.